GEME yields 6.48% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 10
Combined, GEME + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GEME + PFE for your $10,000?
GEME targets the growth potential of emerging markets via a concentrated portfolio of 20-50 equity and equity-related securities. Investments include common stock, preferred stock, and ADRs from large- and mid-cap companies. The fund allocates a minimum of 40% of its assets across multiple non-US countries and 30% during unfavorable conditions. The selection process follows a value-driven approach, seeking undervalued companies trading below intrinsic value, using proprietary valuation models that combine top-down macroeconomic analysis with bottom-up company research. Holdings may include fixed-income securities, participatory notes for restricted markets, and China A-shares, capped at 10%. Additionally, it uses derivatives for currency hedging and may employ up to 15% leverage for long positions, with short positions at 20% strictly reserved for hedging. Positions are sold when they exceed intrinsic value, show deteriorating fundamentals, or increase portfolio risk.
Full GEME Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.